Findings

What do systematic reviews say?

489 questions · 532 findings · 33 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 55 · 10.3%GRADE not reported 28 · 5.3%Very low 119 · 22.4%Low 167 · 31.4%Moderate 129 · 24.2%High 34 · 6.4%

Intervention not reported

MD‐ICS/LABA · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

The review found no eligible studies for this question.

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Total studies: 5 RCTs Total Participants: 7391 · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 7391 participants
GRADE not reported

Intervention not reported

HD‐ICS/LABA (Direct evidence; 2 RCTs; 2817 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 2817 participants
Moderate

Intervention not reported

MD‐TRIPLE (Direct evidence; 2 RCTs; 2237 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 2237 participants
Moderate

Intervention not reported

HD‐TRIPLE (Direct evidence; 1 RCT; 1088 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1088 participants
Moderate

Intervention not reported

MD‐ICS/LABA · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

The review found no eligible studies for this question.

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Outcome№ of participants(studies)

The review found no eligible studies for this question.

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

ACQ responders at 6 months ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of participants: 3700(3 RCTs)

The intervention showed no clear difference in ACQ responders at 6 months ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of… (moderate certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 1.02 [0.96, 1.08]
3 studies · 6 participants
Moderate

Melatonin vs placebo

Total nocturnal sleep time (minutes) · sleep disturbances in dementia

1 finding from 1 review

Pharmacotherapies for sleep disturbances in dementia 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 184 participants
Low

Trazodone vs placebo

Number of nocturnal awakenings · sleep disturbances in dementia

1 finding from 1 review

Pharmacotherapies for sleep disturbances in dementia 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 30 participants
Low

Trazodone vs placebo

Number of participants reporting an adverse event · sleep disturbances in dementia

Trazodone showed no clear difference in reporting ≥ 1 adverse event compared with placebo (low certainty).

1 finding from 1 review

Pharmacotherapies for sleep disturbances in dementia 2020 · Cochrane Headline outcomes only
RR 0.67 [0.23, 1.89]
1 study · 30 participants
Low

Trazodone vs placebo

Cognitive function · sleep disturbances in dementia

1 finding from 1 review

Pharmacotherapies for sleep disturbances in dementia 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 30 participants
Moderate

Trazodone vs placebo

Quality of life · sleep disturbances in dementia

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacotherapies for sleep disturbances in dementia 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Trazodone vs placebo

Carer burden, well‐being or quality of life · sleep disturbances in dementia

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacotherapies for sleep disturbances in dementia 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Orexin antagonists vs placebo

Change from baseline in total nocturnal sleep time · sleep disturbances in dementia

1 finding from 1 review

Pharmacotherapies for sleep disturbances in dementia 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 274 participants
Moderate

Orexin antagonists vs placebo

Consolidated sleep time · sleep disturbances in dementia

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacotherapies for sleep disturbances in dementia 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Orexin antagonists vs placebo

Change from baseline in ratio of number of nocturnal awakenings to total sleep time × 100 · sleep disturbances in dementia

1 finding from 1 review

Pharmacotherapies for sleep disturbances in dementia 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 274 participants
Moderate

Orexin antagonists vs placebo

Number of participants reporting an adverse event · sleep disturbances in dementia

Orexin antagonists showed no clear difference in reporting ≥ 1 adverse event compared with placebo (moderate certainty).

1 finding from 1 review

Pharmacotherapies for sleep disturbances in dementia 2020 · Cochrane Headline outcomes only
RR 1.29 [0.83, 1.99]
2 studies · 323 participants
Moderate

Orexin antagonists vs placebo

Cognitive function · sleep disturbances in dementia

1 finding from 1 review

Pharmacotherapies for sleep disturbances in dementia 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 274 participants
Moderate

Melatonin vs placebo

Consolidated sleep time · sleep disturbances in dementia

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacotherapies for sleep disturbances in dementia 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found